Qinhao Pharma Hong Kong IPO Prospectus Expires on July 16, 2026

According to Zhitong Finance, Qinhao Pharma (Suzhou) Co., Ltd.'s Hong Kong IPO prospectus, filed on January 16, 2026, expired on July 16, 2026, after reaching the six-month validity period. Huatai International served as the sole sponsor for the offering.

Qinhao Pharma is a biopharmaceutical company focused on developing best-in-class targeted therapies in oncology, with a differentiated pipeline centered on RAS signaling pathway and synthetic lethality mechanisms. The company's core product, GH21, is a potential best-in-class allosteric SHP2 inhibitor currently in Phase 2 clinical trials.